I don’t have any info on the price for AMR kits

~

However, I was doing some research on AMR and here is what I have found so far:

• The Global Antimicrobial Resistance Surveillance Market Size was valued at USD 5.61 Billion in 2022. The Market Size is projected to grow at a CAGR of 5.8% from 2022 to 2032
  and is expected to reach USD 9.92 Billion by 2032 Asia Pacific is expected to Grow the fastest during the forecast period [Global Antimicrobial Resistance Surveillance Market Size – 2032.]

• This WHO report on AMR has two sections – one dedicated to TB and another to other drug-resistant bacterial infections. What I infer is TB has much more importance than others bacterial infections [Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis]

• Drug-resistant TB is now estimated to be responsible for 1/3 of all deaths due to antimicrobial resistance (AMR)

• Tuberculosis is a bacterial infection caused by species of the Mycobacterium tuberculosis (TB, MTB) complex. A drug resistant strain is defined as resistance to at least one primary drug used to treat tuberculosis. A multidrug resistant TB (MDR-TB) is defined as resistance to at least isoniazid and rifampicin, the two most effective anti-TB drugs, and an extensively drug resistant TB (XDR-TB) is defined as a MDR-TB strain with additional resistance to any fluoroquinolone and at least one additional Group A drug. In 2022, it was estimated that approximately 4% of incident new TB cases in the world had MDR/RR-TB1.

• MTB RIF/INH resistance test provides identification of rifampicin (RIF) resistance and isoniazid (INH) resistance targeting rpoB, katG and inhA genes

• The world learned of the dangers of antimicrobial resistance with the rise of hospital-acquired infections, like methicillin-resistant Staphylococcus aureus (MRSA). MRSA is a bacterial infection which causes the same infection as SA, however it is dangerous due to its resistance to many antibiotics that successfully treat normal SA.

• 3B BlackBio Dx has the following AMR kits available [see their website]. “3” and “4” are related to TB. Good to see the focus on TB.
  (1) UTI AST Panel Kit
  (2) MRSA Detection Kit
  (3) Rif/INH MTB Drug Resistant Detection Kit
  (4) Rifampicin Resistant MTB Kit

• For Rif/INH MTB Drug Resistant Detection Kit I could find only Abbott and Roche having the kits apart from 3B [https://www.molecular.abbott/int/en/products/infectious-disease/realtime-mtb-rif-inh-resistance , cobas® MTB-RIF/INH]

• For Rifampicin Resistant MTB Kit I see Molbio and Cephid have kits in addition to Abbott and Roche [Molbio Diagnostics Pvt. Ltd., Xpert® MTB/RIF Ultra]

For MRSA and AST I am still on with my research

(post deleted by author)

Though the company has not given Q3FY23 result, it is understood from the already available data.

Sales for Q3FY23 should be 4076 – (1007+911+814) = 1344 Cr
Operating profit should be 330 – (55+33+67) = 175 Cr

Now what I cannot understand is how they got to 13% operating margin that quarter. Though there is operating leverage, do you think it normal for the margin to reach 13% from a meagre 4 – 5% previous quarters? Or am I missing something?

Disc: Invested

@siva_kannan here is where Aether comes too

Pedigree of the management is top notch !!